Can a Louisiana resident get peptides by telehealth?
Act 322 of 2023 (effective January 1, 2024) moved Louisiana's physician telemedicine provisions out of the Medical Practice Act and into the Louisiana Telehealth Access Act. La. R.S. 37:1271 now only requires a license to practice medicine, except as provided in that Act, and the separate telemedicine license statute (R.S. 37:1276.1) was repealed. R.S. 40:1223.3 defines telehealth as healthcare services delivered through electronic communications, information technology, asynchronous store-and-forward transfer technology, or synchronous interaction, and excludes fax and any e-mail or text message that is not HIPAA compliant. R.S. 40:1223.4 requires licensing boards to adopt telehealth rules that apply the in-person standard of care, do not require an in-person history or exam before a telehealth encounter, and require an in-person history or exam before prescribing a controlled dangerous substance unless a rule or R.S. 37:1271.1 allows it. The Board of Medical Examiners has not updated its telemedicine rules (Louisiana Administrative Code 46:XLV.7501 and following, last amended in 2019): section 7503 still defines telemedicine as simultaneous two-way video and audio (audio-only in limited cases), section 7505 says an online, electronic or written mail message does not satisfy the standard of care, and section 7513 bars telemedicine for obesity treatment. Act 345 of 2026 (R.S. 40:1223.4(D), effective May 22, 2026) stops the Board from prohibiting telehealth for obesity or weight management when the provider conducts a synchronous interaction. The Act does not itself require a live visit, but it leaves the Board's obesity rule enforceable against asynchronous obesity care. The Board has proposed a 2026 rule on obesity medication (LAC 46:XLV.6901 and following) that is not yet adopted. This record classifies asynchronous prescribing as not allowed because the Board of Medical Examiners rule in force defines telemedicine as simultaneous two-way video and audio and says an online, electronic or written mail message does not meet the standard of care. That rule speaks of a message rather than a questionnaire by name, and this record treats a questionnaire alone as not enough on that basis. The 2021 and 2023 statutes count asynchronous store-and-forward transfer as telehealth but do not say a relationship may be formed or a drug prescribed that way, and the Board has not revised its rule. [2] [3] [4] [5] [6] [7] [13] [14]
How does the Louisiana pharmacy board treat compounding?
| Board | Louisiana Board of Pharmacy |
|---|---|
| Eligible substances | Follows the federal 503A framework |
The Louisiana Board of Pharmacy regulates pharmacies under the Louisiana Pharmacy Practice Act (La. R.S. Title 37, chapter 14) and its rules in Louisiana Administrative Code Title 46, Part LIII. Louisiana has no separate state bulks list, so peptide eligibility follows the federal 503A framework (approved drug component, USP or NF monograph, or FDA 503A bulks list), and the Board's executive director has stated publicly that compounders may only use bulk substances that meet the federal requirements. Under La. R.S. 37:1232, a pharmacy outside Louisiana that does business in Louisiana must hold a Louisiana pharmacy permit, disclose its officers and pharmacist in charge, submit its latest home-state, FDA, and DEA inspection reports before permitting and every later report after, and keep Louisiana prescription records readily retrievable. The Board's compounding rules are LAC 46:LIII, Chapter 25, Subchapter C (sections 2531 to 2535). Section 2535 requires compounding to comply with the federal Food, Drug and Cosmetic Act, 21 CFR, and all relevant USP-NF chapters; sterile preparations compounded on a patient-specific prescription must meet section 503A and USP chapter 797, and nonsterile ones section 503A and USP chapter 795. A pharmacy must notify the Board and receive approval before starting sterile compounding, products removed from the market for safety may not be used to compound for humans, and copies of commercial products (same active ingredient, strength within 10 percent, same route) require a documented prescriber determination of a clinically significant difference unless the product is discontinued, on the FDA shortage list, or temporarily unavailable. Act 374 of 2026 (Senate Bill 253), signed May 22, 2026 and effective August 1, 2026, enacts La. R.S. 37:23.5. It bars any professional or occupational licensing board from prohibiting a prescriber from providing patients with peptides shipped from an FDA-registered 503B outsourcing facility that complies with 21 U.S.C. 353b or from a 503A compounding pharmacy that complies with 21 U.S.C. 353a and applicable USP-NF chapters. It also bars boards from prohibiting a Louisiana-licensed pharmacist in a state-permitted pharmacy from compounding and dispensing peptides in compliance with 21 U.S.C. 353a and applicable USP-NF chapters. The act protects only compounding that already complies with federal law. It does not make any peptide eligible for 503A or 503B compounding. [1] [8] [9] [10] [11] [12] [15] [16] [21]
Can you get compounded GLP-1s in Louisiana?
In spring 2023, while semaglutide was still in shortage, the Louisiana Board of Pharmacy told in-state compounders to stop compounding semaglutide made from unapproved salt forms (such as semaglutide sodium or acetate) and told out-of-state compounders not to ship such products into Louisiana; the Board's director clarified that compounding with the approved base form was not banned at the time. Since the FDA shortage allowances ended in 2025, compounded semaglutide and tirzepatide are limited to documented patient-specific needs in Louisiana as elsewhere. Act 345 of 2026 protects telehealth for obesity and weight management only when the provider conducts a live, synchronous interaction, and the Board of Medical Examiners rule against telemedicine for obesity treatment remains enforceable against care with no live interaction. [1] [13] [14] [15] [19]
Prices by channel: semaglutide cost, tirzepatide cost.
Approvals, shortage history, and prices for every GLP-1 we track are on the GLP-1 hub.
What is the legal access path in Louisiana?
Access options
Prescriber licensed in Louisiana, in person or by telehealth
Telehealth prescribing of non-controlled peptides is permitted in Louisiana. Expect a live video or phone visit; prescribing without one is not permitted. State law says an online questionnaire alone is not enough.
Pharmacy licensed or registered with the Louisiana Board of Pharmacy
Check the dispensing pharmacy against the board's license lookup before paying, including out-of-state mail-order pharmacies.
Branded GLP-1 through a retail or manufacturer pharmacy
FDA approved semaglutide and tirzepatide are available by prescription. Compounded GLP-1 limited; see the GLP-1 section for why.
CJC-1295 / Ipamorelin from Bodybuilding Peptides
SponsoredPartner lists from $220/month
Tesamorelin / Ipamorelin from Bodybuilding Peptides
SponsoredPartner lists from $274/month
Semax / Selank from Bodybuilding Peptides
SponsoredPartner lists from $274/month
We may earn a commission from these links.
Prices are the partner's own and are not verified by PeptideAgent. You answer health questions after checkout, and the partner's clinician decides whether to prescribe.
Unsponsored access paths are checked against public regulatory records. Sponsored offers are the partner's and are labeled. Products labeled research use only are never listed.
Find a provider in Louisiana
What you'll actually find in Louisiana, and how to check
Licensed compounding pharmacies, clinics, and telehealth prescribers openly offer many unapproved peptides, and prescribers write prescriptions for them. [24] [25] [26]
No FDA oversight of the specific product: FDA does not check a compounded drug's safety, effectiveness, or quality before it is sold. [27]
What Louisiana has done
- Louisiana acted by statute: Act 374, in effect August 1, 2026, bars its licensing boards from prohibiting peptides only when they come from a pharmacy or outsourcing facility that complies with federal compounding law. It does not make any peptide eligible to compound. [21] [29]
Other states have acted:
- On August 19, 2026, Mississippi's medical, nursing, and pharmacy boards said no licensed provider may prescribe, recommend, supply, or administer a peptide that is not FDA approved, and that a consent form does not remove the provider's liability. [30] Mississippi law
Checking the prescriber
Telehealth prescribing of non-controlled peptides is permitted in Louisiana. Expect a live video or phone visit; prescribing without one is not permitted. State law says an online questionnaire alone is not enough. [2] [3] [4] [5] [6] [7] [13] [14] The telehealth rule in full.
Checking the pharmacy
Look the pharmacy up yourself before you pay, including an out-of-state mail-order pharmacy. The pharmacy regulator is the Louisiana Board of Pharmacy; its license search: Louisiana Board of Pharmacy license lookup. [28]
If you're going ahead anyway
These steps lower some risks. They do not make a compounded product safe, and FDA has not reviewed it. [27]
They do not change a peptide's legal status either. That depends on the peptide: for a withdrawn nomination such as BPC-157 or TB-500, a 503A pharmacy has no federal basis to compound it from bulk, with or without a prescription, while a few Category 1 substances, such as NAD+ and glutathione, are compounded under FDA's interim policy, with conditions. Each peptide page gives its status. [17] [31] [32]
Check the pharmacy's license. Look the pharmacy up yourself on your state board of pharmacy's license search; FDA's BeSafeRx page links every state's. If the pharmacy is not listed, or is not licensed in your state, do not use it. [33] [34] [35]
What a legitimate prescription and consult look like. Federal law lets a pharmacy compound only for an identified patient on a valid prescription. A legitimate prescriber is licensed in the state where you are, evaluates you, and tells you the drug is compounded and not FDA approved, and a telehealth company should say which pharmacy compounds it. A seller that needs no prescription, or a pharmacy with no pharmacist to answer questions, is a warning sign. [26] [35] [36]
Why this is safer than a research-use-only product. A state-licensed pharmacy answers to its state board and has a pharmacist you can reach. A product labeled "research use only" or "not for human consumption" has neither, and FDA treats such products sold for people as unapproved drugs. In a 2024 study of semaglutide sold online without a prescription, half of six orders never arrived, and every vial that did was rated probably substandard or falsified, held more drug than its label said, and contained endotoxin. Black-market growth peptides have also contained modified molecules the label did not name. Safer is not safe: compounded drugs can also be contaminated or have too much or too little active ingredient. [27] [37] [38] [39] [40] [41]
Check for:
- A 503A pharmacy licensed in your state (your state board of pharmacy publishes license lookups). [27]
- A real evaluation by a licensed prescriber, not just an online form.
- A certificate of analysis for the specific batch.
Questions to ask
- Pharmacy: What is your license number, and are you licensed in my state? Then check it yourself on the state board's site. [33]
- Telehealth company: Which pharmacy compounds and ships this, and is it a 503A pharmacy or a 503B outsourcing facility? [26]
- Pharmacy: Is this made for me on a prescription written in my name? [36]
- Prescriber: Are you licensed where I am, and will you evaluate me yourself rather than rely on a questionnaire? [26] [35]
- Anyone offering it: Does anyone call it "FDA approved", "generic", or from an "FDA-approved pharmacy"? None of these is true of a compounded drug, so the claim is a red flag. [26]
What is offered for a specific peptide, and what FDA found, is on each peptide page.
Is it legal to buy research peptides in Louisiana?
Only Louisiana-permitted pharmacies, including nonresident pharmacies permitted under La. R.S. 37:1232, may dispense prescription drugs to Louisiana patients. The Louisiana Board of Pharmacy has described semaglutide salt forms sold as "research use only" as not intended for human use, and "research use only" peptides sold for injection are unapproved new drugs under federal law. [8] [15] [20]
Peptide-specific notes for Louisiana
| Peptide | Note |
|---|---|
| Semaglutide | Available branded by prescription. The Louisiana Board of Pharmacy warned in 2023 against compounding with semaglutide salt forms and against shipping such products into Louisiana, and compounded semaglutide base is limited to documented patient-specific needs since the 503A grace period ended April 22, 2025. [15] [19] |
| Tirzepatide | Available branded by prescription, including by live telemedicine from a physician licensed in Louisiana. The Board of Medical Examiners rule defines telemedicine as simultaneous two-way video and audio. Act 345 of 2026 protects telehealth for obesity and weight management only when the provider conducts a synchronous interaction. Compounded tirzepatide is limited to documented patient-specific needs since the 503A grace period ended February 18, 2025. [3] [13] [14] [19] |
| BPC-157 | Not FDA approved and not on the 503A bulks list; its nomination was withdrawn in April 2026. On October 28, 2026 HHS released a draft enforcement discretion policy covering single-ingredient BPC-157 compounded by a state-licensed pharmacy by an allowed route, on a patient-specific prescription, from an FDA-registered manufacturer's tested substance, with serious adverse events reported to FDA. It is not an FDA approval, is not binding, and does not cover blends such as Wolverine. FDA's drug center recommended against listing; the advisory committee voted in favor (HHS policy, Appendix B). The Louisiana Board of Pharmacy has not issued a BPC-157 specific rule, and its stated position is that compounders may use only bulk substances that meet federal requirements. Act 374 of 2026 (La. R.S. 37:23.5) bars Louisiana licensing boards from prohibiting peptide compounding that complies with section 503A, but BPC-157 is still not eligible under 503A until FDA adds it to the bulks list, so state limits still apply alongside the HHS draft. [15] [17] [18] [21] [22] [23] |
Compare: Wegovy vs Zepbound.
Frequently asked questions
Does Louisiana let out-of-state doctors prescribe by telemedicine?
Only with Louisiana authorization. La. R.S. 37:1271 requires a Louisiana license to practice medicine, except as the Louisiana Telehealth Access Act provides. The separate telemedicine license statute (R.S. 37:1276.1) was repealed effective January 1, 2024, and R.S. 40:1223.4 now calls for board rules on licensing or registration of out-of-state telehealth providers. Check the Louisiana State Board of Medical Examiners lookup. [2] [3] [4] [6]
Do I need an in-person visit before a telemedicine GLP-1 prescription in Louisiana?
Not an in-person visit, but a live one. La. R.S. 40:1223.4 says a provider is not required to conduct an in-person history or exam before a telehealth encounter, though the same standard of care applies. The in-person requirement applies to controlled dangerous substances, and GLP-1 drugs are not controlled. The Board of Medical Examiners rule defines telemedicine as simultaneous two-way video and audio and says an online, electronic or written mail message does not meet the standard of care, so a message exchange alone is not enough. For obesity or weight management, Act 345 of 2026 protects telehealth only when the provider conducts a live, synchronous interaction with you. [6] [7] [13] [14]
Did Louisiana ban compounded semaglutide?
Not outright. In 2023 the Louisiana Board of Pharmacy told pharmacies to stop compounding with unapproved semaglutide salt forms and not to ship them into Louisiana, and its director said compounding with the approved form was still allowed then. Since the FDA shortage ended in 2025, compounded semaglutide is limited to documented patient-specific needs. [15] [19]
What does an out-of-state pharmacy need to ship compounded peptides to Louisiana?
A Louisiana Board of Pharmacy permit under La. R.S. 37:1232. The pharmacy must give the Board its latest inspection reports from its home state, FDA, and DEA, and keep Louisiana prescription records readily retrievable. Verify the permit on the Board's lookup before ordering. [1] [8]
Can a Louisiana pharmacy compound BPC-157?
Only under a draft federal policy, and only within strict limits. On October 28, 2026 HHS released a draft enforcement discretion policy saying it will not take enforcement action against a state-licensed pharmacy that compounds BPC-157 as a single-ingredient product by an allowed route, on a patient-specific prescription, from an FDA-registered manufacturer's substance with a tested certificate of analysis, with serious adverse events reported to FDA. BPC-157 is still not FDA approved or on the 503A bulks list, the policy is not binding and HHS may revisit it, and blends such as Wolverine are not covered. FDA's drug center recommended against listing BPC-157; the advisory committee voted in favor (HHS policy, Appendix B). State law still applies: Louisiana has no separate state bulks list, and the Board's executive director has stated publicly that compounders may only use bulk substances that meet the federal requirements. Act 374 of 2026 bars licensing boards from prohibiting peptide compounding that complies with section 503A, but it does not make any peptide eligible for 503A compounding, so state limits still apply. [15] [17] [18] [21] [22] [23]
Does Louisiana's 2026 peptide law allow any compounded peptide?
No. Act 374 of 2026 (La. R.S. 37:23.5, effective August 1, 2026) stops Louisiana licensing boards from banning peptides that come from a 503A pharmacy or 503B outsourcing facility complying with federal compounding law. A peptide that is not eligible under federal law, such as one not on the 503A bulks list, still has no federal basis to be compounded, so Act 374 does not reach it. [16] [21]
From the blog
- Can you get a GLP-1 through telehealth in your state?
Yes in every state, but the rules for the visit, the prescriber's license, and the pharmacy differ. How state telehealth law shapes GLP-1 access, with state examples.
Sources
Numbered citations above point to these primary sources: the state statute or rule, the pharmacy board, federal FDA guidance, and the FDA warning letters and studies behind what is offered.
- [1]Louisiana Board of Pharmacy
- [2]Louisiana State Board of Medical Examiners
- [3]La. R.S. 37:1271, License to practice medicine required (Louisiana State Legislature, text effective January 1, 2024)
- [4]Louisiana Act 322 of 2023 (Senate Bill 66), telehealth: amends R.S. 37:1262(4), 37:1271 and 40:1223.3 to 1223.5, repeals R.S. 37:1276.1
- [5]La. R.S. 40:1223.3, Louisiana Telehealth Access Act definitions (Louisiana State Legislature)
- [6]La. R.S. 40:1223.4, Telehealth; rulemaking required (Louisiana State Legislature)
- [7]Louisiana Administrative Code Title 46, Part XLV, section 7503, Telemedicine definitions (LSBME rules)
- [8]La. R.S. 37:1232, Nonresident pharmacy
- [9]Louisiana Board of Pharmacy: Title 37, chapter 14, Pharmacy Practice Act
- [10]Louisiana Administrative Code Title 46, Part LIII, Pharmacists (Board of Pharmacy rules)
Cite this page
Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.
- APA style
PeptideAgent. (2026, October 28). Are peptides legal in Louisiana?. https://peptideagent.ai/legal/louisiana- HTML link
<a href="https://peptideagent.ai/legal/louisiana">Are peptides legal in Louisiana?</a>, PeptideAgent, updated October 28, 2026.